Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,053.58
(
-0.12%
)
News Focus
News Focus
Post# of 2446
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Democritus_of_Abdera post# 2132

Wednesday, 11/12/2008 3:24:12 AM

Wednesday, November 12, 2008 3:24:12 AM

Post# of 2446
OctoPlus to Conduct Drug-Delivery Feasibility Study for Unnamed US-Based Biotech

http://biz.yahoo.com/iw/081112/0451652.html

›Wednesday November 12, 2:18 am ET

LEIDEN, NETHERLANDS--(MARKET WIRE)--Nov 12, 2008 -- As part of the Company's recently announced strategic focus on developing controlled release formulations for clients, OctoPlus N.V. ("OctoPlus" or "the Company") (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a US-based biotech company.

On 6 October, OctoPlus announced a licensing agreement with Biolex Therapeutics, to license Locteron®, a product based on OctoPlus' PolyActive® drug delivery technology, to Biolex. OctoPlus' strategy will increasingly focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing. Currently, OctoPlus is working on five projects to develop a controlled release formulation for a client.

Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.‹

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent SRDX News
More SRDX News